Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a topical FOL-005 dose-finding trial in men with androgenetic alopecia
2019-004305-26Phase 2Completed
- Sponsor
- Follicum
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Follicopeptide in androgenetic alopecia (AGA) (4 arms), sponsored by Follicum. Primary endpoint: Change in total hair density. Started Nov 2019; status: completed.
02
Drugs
Follicopeptide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on 2019-004305-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004305-26.